[News of the year 2005 in sarcomas].
This year, the innovations were numerous in sarcomas. Important progress were accomplished in the search for predictive factors which make it possible to propose to the patient a personalized treatment with the therapeutic ones reduced in the event of good prognosis or on the contrary aggressive steps in the event of bad prognosis. These prognostic factors can be genetic or clinical. Progress were also accomplished in the clinical field with the research of the most adapted therapeutic strategies and of advanced in various drugs of chemotherapy in particular the ET-743. Lastly, research is active and of many ways are tested into preclinic with a detailed attention on the way of the angiogenesis.
Fayette
Jérôme
J
Hôpital Edouard-Herriot, Service d'oncologie médicale, Pavillon E, 5 place d'Arsonval, 69003 Lyon. jfayette@free.fr
Méeus
Pierre
P
Sunyach
Marie-Pierre
MP
Thiesse
Philippe
P
Ray Coquard
Isabelle
I
Blay
Jean-Yves
JY
D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D004149:Dioxoles / Q000494:pharmacology / Q000627:therapeutic use*; D005819:Genetic Markers; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology / Q000627:therapeutic use*; D009389:Neovascularization, Pathologic; D010347:Patient Care Planning; D011379:Prognosis; D012509:Sarcoma / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin
D018906:Antineoplastic Agents, Alkylating; D014408:Biomarkers, Tumor; D004149:Dioxoles; D005819:Genetic Markers; D007546:Isoquinolines; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin